Innate immunity modulates autoimmunity: type 1 interferon‐β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation
Open accessThe DOI matches its Crossref record.
Abstract
Summary: Type 1 interferon‐β (T1IFN‐β) is an innate cytokine and the first‐choice therapy for multiple sclerosis (MS). It is still unclear how T1IFN‐β, whose main function is to promote innate immunity during infections, plays a beneficial role in autoimmune disease. Here we show that T1IFN‐β promoted the expansion and function of invariant natural killer (iNKT) cells, an innate T‐cell subset with strong immune regulatory properties that is able to prevent autoimmune disease in pre‐clinical models of MS and type 1 diabetes. Specifically, we observed that T1IFN‐β treatment significantly increased the percentages of Vα24+ NKT cells in peripheral blood mononuclear cells of MS patients. Furthermore, iNKT cells of T1IFN‐β‐treated individuals showed a dramatically improved secretion of cytokines (interleukins 4 and 5 and interferon‐γ) in response to antigenic stimulation compared to iNKT cells isolated from the same patients before T1IFN‐β treatment. The effect of T1IFN‐β on iNKT cells was mediated through the modulation of myeloid dendritic cells (DCs). In fact, DCs modulated in vivo or in vitro by T1IFN‐β were more efficient antigen‐presenting cells for iNKT cells. Such a modulatory effect of T1IFN‐β was associated with up‐regulation on DCs of key costimulatory molecules for iNKT (i.e. CD80, CD40 and CD1d). Our data identified the iNKT cell/DC pathway as a new target for the immune regulatory effect of T1IFNs in autoimmune diseases and provide a possible mechanism to explain the clinical efficacy of T1IFN‐β in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Presumed guilty: natural killer T cell defects and human disease
Berzins, S. P., Smyth, M. J., & Baxter, A. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2904 · Cited by 365
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
Metadata
- Authors
- Gigli, G., Caielli, S., Cutuli, D., & Falcone, M.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2007-07-06
- Volume
- 122
- Issue
- 3
- Pages
- 409-417
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2045628800
- Cited by
- 50
- References
- 0
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Innate immunity modulates autoimmunity: type 1 interferon‐β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. https://app.cochat.ai/papers/10.1111/j.1365-2567.2007.02655.x
- The paper
- Gigli, G., Caielli, S., Cutuli, D., & Falcone, M. (2007). Innate immunity modulates autoimmunity: type 1 interferon‐β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology. https://doi.org/10.1111/j.1365-2567.2007.02655.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.